Rule 17 Never Uses the Word

A company's power to buy back its own securities sits in Section 68 of the Companies Act, 2013, with the procedure for private and unlisted public companies in Rule 17 of the Companies (Share Capital and Debentures) Rules, 2014. Checked directly against the current text of Rule 17, the words "valuation," "valuer" and "registered valuer" do not appear anywhere in it.

What it requires instead are two narrower things.

  • Disclosure, not certification. The explanatory statement to the notice convening the buy-back meeting must state the buy-back price and the basis for arriving at it. Nobody has to certify that the basis is fair.
  • An auditor's report, on a different question. The auditors must certify that they have inquired into the state of the company's affairs, that the permissible capital payment is properly determined, that the accounts used are not more than six months old, and that the company will not be rendered insolvent within a year. A solvency and quantum check on the total amount spent, not a fairness opinion on the per-share price.

Compare Section 62(1)(c) preferential allotments, where Rule 13(2)(g) requires a registered valuer's report before the price is fixed. Rule 17 has no equivalent.

The Listed Side Reaches the Same Answer by Two Other Routes

Listed companies buy back under the SEBI (Buy-Back of Securities) Regulations, 2018, through one of two routes.

  • Tender offer. Price is set within SEBI's own pricing framework, with a merchant banker managing the offer process. The merchant banker administers the offer; it does not issue a fairness opinion on price.
  • Open market, through the exchange. Capped at a percentage of paid-up capital plus free reserves. The price is whatever the market trades at, so there is nothing to value independently.

Neither route carries a registered-valuer requirement. Same answer on both sides of the listed line, for different structural reasons: no market price to defer to for unlisted companies, and either a regulated formula or an actual trading market for listed ones.

The Gap Follows From What the Mandate Protects

This is not a drafting oversight. A preferential allotment dilutes shareholders who are not part of it. They have no say in the price and no opportunity to participate, so the law inserts an independent valuer between the company and the incoming investor. Sweat equity has the same problem in reverse: shares are handed out for something other than cash, so a valuer checks both the share price and the thing being paid for.

A buy-back has no such problem. Every shareholder gets the same opportunity to participate, pro rata, on the same terms, and nobody is forced to sell. The people the law is worried about here are creditors, since cash is leaving the company to pay shareholders instead of debts. That is exactly what the solvency declaration and the auditor's certificate are for. A fairness opinion would be solving a problem the mechanism does not have.

The Pattern Holds Across the Series

ESOP and buy-backs both turn out to have no company-law valuer mandate, while sweat equity and preferential allotments both require one. The pattern is never about the size of the transaction. It is always about who the law is trying to protect.

Mergers land in the middle, covered in Merger Valuations: Conditional Under Company Law, Mandatory Under SEBI: conditional under company law, unavoidable in practice. A preference share redemption sits in the same "nothing left to price" family, covered in Preference Shares Are an SFA Valuer's Job. Redemption Isn't. And because every shareholder gets the same pro-rata offer and nobody's control position changes, a buy-back is the clean contrast case for control premium, covered in Control Premium: Explicit Duty Under IBC, Implicit Duty Everywhere Else.

The income tax side lines up too. Buy-backs are excluded from both Section 50CA and Section 56(2)(x), covered in Angel Tax Is Abolished. Rule 11UA Isn't, since Section 115QA governs buy-back taxation on its own non-obstante terms.

What This Means in Practice

Commission the valuation anyway, and be clear with the board about what it is. A defensible, methodology-backed price is what gives the auditor's "properly determined" certification something rigorous to rely on, and what a board wants on file if the price is ever questioned.

But do not describe it as a compliance requirement. Two engagements can wear the same DCF methodology and be legally different things: one a statutory requirement with a rule behind it, the other governance practice with no rule mandating it.

No valuer mandate on the company-law side. No Rule 11UA exposure on the tax side. Only a solvency question, and creditors are the ones asking it.